Results 271 to 280 of about 44,321 (338)

TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B‐Cell Lymphoma in the Real‐Life Patient Journey

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT The combination of tafasitamab and lenalidomide (tafa‐lena) has demonstrated efficacy in relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL), as evidenced by the L‐MIND study. To investigate the therapeutic potential and safety profile of tafa‐lena in real‐life, we conducted a national multicentric retrospective study.
Lisa Argnani, Cinzia Pellegrini, Ombretta Annibali, Piera Angelillo, Enrico Amaducci, Filippo Ballerini, Flaminia Bellisario, Andrea Bernardelli, Riccardo Bruna, Catello Califano, Giusy Cetani, Giulia Daghia, Enrico Derenzini, Antonio Frolli, Francesco Gaudio, Valerio Guarente, Ausilia Gorgone, Liardo Eliana Valentina, Elisa Lucchini, Dario Marino, Luca Nassi, Paolo Nicoli, Mattia Novo, Francesca Palombi, Caterina Patti, Vincenzo Pavone, Marcello Riva, Filomena Russo, Greta Scapinello, Alessandro Severino, Monica Tani, Daniele Vallisa, Beatrice Casadei, Alessandro Broccoli, Pier Luigi Zinzani   +34 more
wiley   +1 more source

Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement. [PDF]

Blood Cancer J
Steinhardt MJ, Schaefers C, Leypoldt LB, Blau IW, Harzer M, Zhou X, Riedhammer C, Kamili A, Kosch R, Topp LS, Molwitz I, Gross-Fengels NO, Melzer YF, Artzenroth J, Al-Bazaz M, Alsdorf W, Topp MS, Duell J, Mersi J, Waldschmidt J, Bokemeyer C, Einsele H, Kortüm KM, Weisel K, Rasche L.   +24 more
europepmc   +1 more source

Rebalancing Hemostasis: Fitusiran as a First‐in‐Class RNAi Therapy in Hemophilia A and B

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims Fitusiran is a first‐in‐class RNA interference (RNAi) therapy that lowers antithrombin (AT) to rebalance hemostasis in people with Hemophilia A or B, with or without inhibitors. Its recent FDA approval marks a major shift toward factor‐independent prophylaxis.
Raza Ur Rehman, Rida Fatima, Aymar Akilimali   +2 more
wiley   +1 more source

Bispecific antibodies combined with chemotherapy in solid tumor treatment, the path forward? [PDF]

Front Immunol
Yan Y, Yuan J, Peng Y, Zhou C, Liu X, Sun L, Song Q.   +6 more
europepmc   +1 more source

Patient‐Reported Symptom and Symptom Clusters During Immune Checkpoint Inhibitor Therapy for Cancer Patients: A Cross‐Sectional Survey

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims Cancer treatment management necessitates comprehensive symptom burden assessment, particularly with therapies like immune checkpoint inhibitors (ICIs), known for unique toxicities. While ICIs show promising outcomes, they also induce immune‐related adverse events (irAEs), posing challenges due to their varied onset ...
Simeng Ren, Jingqi Yang, Hongkun Xu, Jiayue Jin, Shuo Wang, Baojin Han, Wenzheng Zhang, Yutong Lv, Jie Liu   +8 more
wiley   +1 more source

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium. [PDF]

Blood Adv
Melody M, Grover N, Franco S, Romancik J, Cortese M, Moyo TK, Bhansali RS, Ollila T, Kenkre V, Fitzgerald L, Hess B, Matasar M, Shouse G, Annunzio K, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Ma S, Winter JN, Lin A, Danilov A, Roy I, Barta SK, Gordon LI, Stephens D, Cohen JB, Epperla N, Karmali R.   +29 more
europepmc   +1 more source

Anti‐PD‐1/PD‐L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims Anti‐PD‐1/PD‐L1 immunotherapy has changed the treatment landscape of lung cancer. This new approach provides the ability to revitalize the immune system to specifically target and kill cancer cells, thereby creating a new treatment paradigm for patients with non‐small cell lung cancer (NSCLC).
Md Mohiuddin
wiley   +1 more source

Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma. [PDF]

Blood Adv
Adegbite B, Tan CR, Shekarkhand T, Firestone RS, Jurgens EM, Miller K, Lesokhin AM, Shah GL, Korde N, Rajeeve S, Landau HJ, Scordo M, Hassoun H, Maclachlan KH, Shah UA, Hultcrantz M, Hamadeh IS, Derkach A, Nemirovsky D, Giralt SA, Mailankody S, Usmani SZ, Hashmi H.   +22 more
europepmc   +1 more source

Balancing Promise and Peril: Hemophilia Gene Therapy Insights

IUBMB Life, Volume 78, Issue 1, January 2026.
ABSTRACT Hemophilia is an inherited disorder characterized by impaired blood clotting caused by mutations in the genes responsible for producing coagulation factor (F) VIII (hemophilia A, HA) or FIX (hemophilia B, HB). Current treatment primarily relies on replacement therapy, involving frequent and costly infusions of FVIII or FIX concentrates.
Saicharan Akula, Ester Borroni, Alessia Cottonaro, Antonia Follenzi, Simone Merlin   +4 more
wiley   +1 more source

Co-phagocytosis of VEGFA with HER2-overexpressing cancer cells induced by HER2-VEGFA-bispecific antibodies improves antitumor responses. [PDF]

JCI Insight
Lu Y, Qiu S, Fan Z.
europepmc   +1 more source